newsantibody-drug conjugatesgynecologic cancers
Real-World Antibody-Drug Conjugate Outcomes in Gynecologic Cancers Appear Consistent Across Demographic Subgroups
By MedXY|May 4, 2026
In a single-center real-world cohort, survival with mirvetuximab soravtansine, trastuzumab deruxtecan, and tisotumab vedotin broadly mirrored pivotal trials, with no independent survival differences by age, race, or ethnicity after adjustme
